ijms-logo

Journal Browser

Journal Browser

Cancer Cell Metabolism 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 16892

Special Issue Editors

Department of Surgery, University Medical Centre Regensburg, Regensburg, Germany
Interests: prostate cancer; metabolism; transporter; citrate; cancer associated stroma; metastasis; mitochondria
Department of Dermatology, University Medical Centre, Regensburg, Germany
Interests: cutaneous melanoma; metabolism; metastasis
Special Issues, Collections and Topics in MDPI journals
Centre for Immunobiology and Regenerative Medicine, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK
Interests: ageing; senescence; oral cancer; squamous cell carcinoma; metabolism; cell cycle
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue “Cancer Cell Metabolism 2.0” is a continuation of the successful 2020 issue “Cancer Cell Metabolism” Cancer cells require excess energy and metabolite synthesis to successfully grow and metastasize. Therefore, their metabolism has to be particularly efficient. Moreover, changing extracellular conditions require that cancer cells have significant flexibility and use different pathways and supplies to supplement potentially missing metabolites. To secure the necessary substrates, cancer cells rely on the surrounding stroma and newly formed blood vessels. They also modify their metabolism and involve the tumor environment to increase their resistance to anticancer therapies. Not surprisingly, cancer cell metabolism differs significantly from its healthy counterpart and is exploited diagnostically and therapeutically. For this Special Issue, we invite the submission of research articles and reviews on metabolic mechanisms supporting tumor metastases, organ colonization, escape from immune defense, and therapeutic resistance as well as metabolic interactions with the stroma. We would like input from basic, translational, and preclinical studies.

Dr. Maria E. Mycielska
Dr. Sebastian Haferkamp
Prof. Dr. Eric Parkinson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • metabolism
  • metastasis
  • colonization
  • therapy resistance
  • cancer associated stroma
  • immune cells
  • diagnostics

Published Papers (9 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2547 KiB  
Article
3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells
by Patrik da Silva Vital, Murilo Bonatelli, Marina Pereira Dias, Larissa Vedovato Vilela de Salis, Mariana Tomazini Pinto, Fátima Baltazar, Silvya Stuchi Maria-Engler and Céline Pinheiro
Int. J. Mol. Sci. 2022, 23(24), 15650; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232415650 - 09 Dec 2022
Cited by 4 | Viewed by 1600
Abstract
(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates remain challenging, [...] Read more.
(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates remain challenging, even with contemporary therapeutic alternatives. Highly proliferative tumors often rely on glycolysis to sustain their aggressive phenotype. 3-bromopyruvate (3BP) is a promising glycolysis inhibitor reported to mitigate resistance in tumors. This study aimed to evaluate the potential of 3BP as an antineoplastic agent for PLX-resistant melanoma treatment. (2) The effect of 3BP alone or in combination with PLX on viability, proliferation, colony formation, cell death, migration, invasion, epithelial-mesenchymal marker and metabolic protein expression, extracellular glucose and lactate, and reactive species were evaluated in two PLX-resistant melanoma cell lines. (3) 3BP treatment, which was more effective as monotherapy than combined with PLX, disturbed the metabolic and epithelial-mesenchymal profile of PLX-resistant cells, impairing their proliferation, migration, and invasion and triggering cell death. (4) 3BP monotherapy is a potent metabolic-disrupting agent against PLX-resistant melanomas, supporting the suppression of the malignant phenotype in this type of neoplasia. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Graphical abstract

19 pages, 3993 KiB  
Article
Cancer Stem Cell Formation Induced and Regulated by Extracellular ATP and Stanniocalcin-1 in Human Lung Cancer Cells and Tumors
by Jingwen Song, Yanrong Qian, Maria Evers, Corinne M. Nielsen and Xiaozhuo Chen
Int. J. Mol. Sci. 2022, 23(23), 14770; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314770 - 25 Nov 2022
Cited by 4 | Viewed by 1911
Abstract
Cancer stem cells (CSCs) are closely associated with metastasis and epithelial mesenchymal transition (EMT). We previously reported that extracellular ATP (eATP) induces and regulates EMT in cancer cells. We recently found that the gene stanniocalcin 1 (STC1) is significantly upregulated by [...] Read more.
Cancer stem cells (CSCs) are closely associated with metastasis and epithelial mesenchymal transition (EMT). We previously reported that extracellular ATP (eATP) induces and regulates EMT in cancer cells. We recently found that the gene stanniocalcin 1 (STC1) is significantly upregulated by eATP in human non-small lung cancer (NSCLC) A549 cells; however, the relationships among eATP, CSCs, and STC1 were largely unknown. In this study, we performed gene knockdown and knockout, and a wide variety of functional assays to determine if and how eATP and STC1 induce CSCs in NSCLC A549 and H1299 cells. Our data show that, in both cultured cells and tumors, eATP increased the number of CSCs in the cancer cell population and upregulated CSC-related genes and protein markers. STC1 deletion led to drastically slower cell and tumor growth, reduced intracellular ATP levels and CSC markers, and metabolically shifted STC1-deficient cells from an energetic state to a quiescent state. These findings indicate that eATP induces and regulates CSCs at transcriptional, translational, and metabolic levels, and these activities are mediated through STC1 via mitochondria-associated ATP synthesis. These novel findings offer insights into eATP-induced CSCs and identify new targets for inhibiting CSCs. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

12 pages, 2213 KiB  
Article
Glucuronidated Metabolites of Bisphenols A and S Alter the Properties of Normal Urothelial and Bladder Cancer Cells
by Ève Pellerin, Félix-Antoine Pellerin, Stéphane Chabaud, Frédéric Pouliot, Martin Pelletier and Stéphane Bolduc
Int. J. Mol. Sci. 2022, 23(21), 12859; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232112859 - 25 Oct 2022
Cited by 2 | Viewed by 1116
Abstract
Bisphenol A (BPA) and bisphenol S (BPS) are synthetic chemicals used to produce plastics which can be released in food and water. Once ingested, BPA and BPS are metabolized by the liver, mainly as glucuronidated metabolites, and are excreted through urine. Since urine [...] Read more.
Bisphenol A (BPA) and bisphenol S (BPS) are synthetic chemicals used to produce plastics which can be released in food and water. Once ingested, BPA and BPS are metabolized by the liver, mainly as glucuronidated metabolites, and are excreted through urine. Since urine can be stored for many hours, the bladder is chronically exposed to BP metabolites, and studies have shown that these metabolites can remain active in the organism. Therefore, the effect of physiological concentrations of glucuronidated BPs was evaluated on the bioenergetics (glycolysis and mitochondrial respiration), migration and proliferation of normal urothelial cells, and non-invasive and invasive bladder cancer cells. The results demonstrated that an exposure of 72 h to glucuronidated BPA or BPS decreased the bioenergetics and activity of normal urothelial cells, while increasing these parameters for bladder cancer cells. These findings suggest that BP metabolites are not as inactive as initially believed, and their ubiquitous presence in the urine could promote bladder cancer progression. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

19 pages, 4163 KiB  
Article
Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics
by Ildikó Krencz, Enikő Vetlényi, Titanilla Dankó, Gábor Petővári, Dorottya Moldvai, Dániel Sztankovics, Regina Raffay, Katalin Mészáros, Endre Sebestyén, Gyula Végső, Judit Pápay and Anna Sebestyén
Int. J. Mol. Sci. 2022, 23(18), 10587; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms231810587 - 13 Sep 2022
Cited by 4 | Viewed by 1776
Abstract
Metabolic characteristics of kidney cancers have mainly been obtained from the most frequent clear cell renal cell carcinoma (CCRCC) studies. Moreover, the bioenergetic perturbances that affect metabolic adaptation possibilities of papillary renal cell carcinoma (PRCC) have not yet been detailed. Therefore, our study [...] Read more.
Metabolic characteristics of kidney cancers have mainly been obtained from the most frequent clear cell renal cell carcinoma (CCRCC) studies. Moreover, the bioenergetic perturbances that affect metabolic adaptation possibilities of papillary renal cell carcinoma (PRCC) have not yet been detailed. Therefore, our study aimed to analyze the in situ metabolic features of PRCC vs. CCRCC tissues and compared the metabolic characteristics of PRCC, CCRCC, and normal tubular epithelial cell lines. The protein and mRNA expressions of the molecular elements in mammalian target of rapamycin (mTOR) and additional metabolic pathways were analyzed in human PRCC cases compared to CCRCC. The metabolic protein expression pattern, metabolite content, mTOR, and metabolic inhibitor sensitivity of renal carcinoma cell lines were also studied and compared with tubular epithelial cells, as “normal” control. We observed higher protein expressions of the “alternative bioenergetic pathway” elements, in correlation with the possible higher glutamine and acetate consumption in PRCC cells instead of higher glycolytic and mTOR activity in CCRCCs. Increased expression of certain metabolic pathway markers correlates with the detected differences in metabolite ratios, as well. The lower lactate/pyruvate, lactate/malate, and higher pyruvate/citrate intracellular metabolite ratios in PRCC compared to CCRCC cell lines suggest that ACHN (PRCC) have lower Warburg glycolytic capacity, less pronounced pyruvate to lactate producing activity and shifted OXPHOS phenotype. However, both studied renal carcinoma cell lines showed higher mTOR activity than tubular epithelial cells cultured in vitro, the metabolite ratio, the enzyme expression profiles, and the higher mitochondrial content also suggest increased importance of mitochondrial functions, including mitochondrial OXPHOS in PRCCs. Additionally, PRCC cells showed significant mTOR inhibitor sensitivity and the used metabolic inhibitors increased the effect of rapamycin in combined treatments. Our study revealed in situ metabolic differences in mTOR and metabolic protein expression patterns of human PRCC and CCRCC tissues as well as in cell lines. These underline the importance in the development of specific new treatment strategies, new mTOR inhibitors, and other anti-metabolic drug combinations in PRCC therapy. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

15 pages, 2722 KiB  
Article
Identification and Validation of TRIM25 as a Glucose Metabolism Regulator in Prostate Cancer
by Chao Li, Peng Dou, Xin Lu, Pengwei Guan, Zhikun Lin, Yanyan Zhou, Xin Lu, Xiaohui Lin and Guowang Xu
Int. J. Mol. Sci. 2022, 23(16), 9325; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23169325 - 19 Aug 2022
Cited by 2 | Viewed by 1679
Abstract
Prostate cancer (PCa) malignant progression is accompanied with the reprogramming of glucose metabolism. However, the genes involved in the regulation of glucose metabolism in PCa are not fully understood. Here, we propose a new method, DMRG, which constructs a weighted differential network (W-K-DN) [...] Read more.
Prostate cancer (PCa) malignant progression is accompanied with the reprogramming of glucose metabolism. However, the genes involved in the regulation of glucose metabolism in PCa are not fully understood. Here, we propose a new method, DMRG, which constructs a weighted differential network (W-K-DN) to define the important metabolism-related genes. Based on biological knowledge and prostate cancer transcriptome data, a tripartite motif-containing 25 (TRIM25) was defined using DMRG; TRIM25 was involved in the regulation of glucose metabolism, which was verified by overexpressing or knocking down TRIM25 in PCa cell lines. Differential expression analysis of TCA cycle enzymes revealed that TRIM25 regulated isocitrate dehydrogenase 1 (IDH1) and fumarate hydratase (FH) expression. Moreover, a protein–RNA interaction network of TRIM25 revealed that TRIM25 interacted with RNA-binding proteins, including DExH-box helicase 9 and DEAD-box helicase 5, to play a role in regulating the RNA processing of metabolic enzymes, including IDH1 and FH. Furthermore, TRIM25 expression level was found to be positively correlated with Gleason scores in PCa patient tissues. In conclusion, this study provides a new method to define genes influencing tumor progression, and sheds light on the role of the defined TRIM25 in regulating glucose metabolism and promoting PCa malignancy. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

23 pages, 8343 KiB  
Article
New Peptide Functionalized Nanostructured Lipid Carriers with CNS Drugs and Evaluation Anti-proliferative Activity
by Sara Silva, Joana Marto, Lídia M. Gonçalves, Diana Duarte, O. Salomé G. P. Soares, Francisco Vasques-Nóvoa, António J. Almeida and Nuno Vale
Int. J. Mol. Sci. 2022, 23(13), 7109; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23137109 - 26 Jun 2022
Cited by 2 | Viewed by 1841
Abstract
Nanoparticulate systems have been widely investigated as delivery vectors for efficient drug delivery in different diseases. Nanostructured lipid carriers (NLC) are composed of both solid and liquid lipids (glyceryl dibehenate and diethylene glycol monoethyl ether) and have demonstrated enhanced biological compatibility and increased [...] Read more.
Nanoparticulate systems have been widely investigated as delivery vectors for efficient drug delivery in different diseases. Nanostructured lipid carriers (NLC) are composed of both solid and liquid lipids (glyceryl dibehenate and diethylene glycol monoethyl ether) and have demonstrated enhanced biological compatibility and increased drug loading capability. Furthermore, the use of peptides, in particular cell-penetrating peptides, to functionalize nanoparticles and enhance cell membrane permeation was explored in this paper. In this paper, we described the synthesis of a new conjugated of tranylcypromine with MAP. In addition, taking into consideration our previous results, this study developed different NLCs loaded with three central nervous system (CNS) drugs (tacrine (TAC), rasagiline (RAS), and tranylcypromine (TCP)) functionalized with model amphipathic peptide (MAP) and evaluated their activity against cancer cells. Particle size analysis demonstrated NLC presented less than 200 nm and a polydispersity index less than 0.3. Moreover, in vitro results showed that conjugation of MAP with drugs led to a higher decrease in cell viability of a neuroblastoma cell line and Caco-2 cell line, more than MAP alone. Furthermore, NLC encapsulation contributed to higher cellular delivery and enhanced toxic activity at lower concentrations when compared with free or co-administration drug-MAP conjugate. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

13 pages, 5055 KiB  
Article
Effect of Compressive Stress in Tumor Microenvironment on Malignant Tumor Spheroid Invasion Process
by Ryota Nishi, Yudai Oda, Takashi Morikura and Shogo Miyata
Int. J. Mol. Sci. 2022, 23(13), 7091; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23137091 - 25 Jun 2022
Viewed by 1806
Abstract
In this study, we proposed an in vitro tumor model to simulate the mechanical microenvironment and investigate the effect of compressive stress on the invasion process of malignant tumors. It has been pointed out that the biomechanical environment, as well as the biochemical [...] Read more.
In this study, we proposed an in vitro tumor model to simulate the mechanical microenvironment and investigate the effect of compressive stress on the invasion process of malignant tumors. It has been pointed out that the biomechanical environment, as well as the biochemical environment, could affect the transformation of cancer cell migration, invasion, and metastasis. We hypothesized that the solid stress caused by the exclusion of surrounding tissue could transform tumor cells from noninvasive to invasive phenotypes. Colorectal cell spheroids were embedded and cultured in agarose gels of varying concentrations to simulate the earliest stages of tumor formation and invasion. The spheroids embedded in gels at higher concentrations showed peculiar growth after 72 h of culture, and the external compressive loading imposed on them caused peculiar growth even in the gels at lower concentrations. In conclusion, the mechanical microenvironment caused the transformation of tumor cell phenotypes, promoting the growth and invasion of tumor cell spheroids. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

20 pages, 3545 KiB  
Article
LDHB Overexpression Can Partially Overcome T Cell Inhibition by Lactic Acid
by Sonja-Maria Decking, Christina Bruss, Nathalie Babl, Sebastian Bittner, Sebastian Klobuch, Simone Thomas, Markus Feuerer, Petra Hoffmann, Katja Dettmer, Peter J. Oefner, Kathrin Renner and Marina Kreutz
Int. J. Mol. Sci. 2022, 23(11), 5970; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23115970 - 26 May 2022
Cited by 12 | Viewed by 2571
Abstract
Accelerated glycolysis leads to secretion and accumulation of lactate and protons in the tumor environment and determines the efficacy of adoptive T cell and checkpoint inhibition therapy. Here, we analyzed effects of lactic acid on different human CD4 T cell subsets and aimed [...] Read more.
Accelerated glycolysis leads to secretion and accumulation of lactate and protons in the tumor environment and determines the efficacy of adoptive T cell and checkpoint inhibition therapy. Here, we analyzed effects of lactic acid on different human CD4 T cell subsets and aimed to increase CD4 T cell resistance towards lactic acid. In all CD4 T cell subsets analyzed, lactic acid inhibited metabolic activity (glycolysis and respiration), cytokine secretion, and cell proliferation. Overexpression of the lactate-metabolizing isoenzyme LDHB increased cell respiration and mitigated lactic acid effects on intracellular cytokine production. Strikingly, LDHB-overexpressing cells preferentially migrated into HCT116 tumor spheroids and displayed higher expression of cytotoxic effector molecules. We conclude, that LDHB overexpression might be a promising strategy to increase the efficacy of adoptive T cell transfer therapy. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

18 pages, 3771 KiB  
Article
The Wnt Signaling Pathway Inhibitors Improve the Therapeutic Activity of Glycolysis Modulators against Tongue Cancer Cells
by Robert Kleszcz and Jarosław Paluszczak
Int. J. Mol. Sci. 2022, 23(3), 1248; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23031248 - 23 Jan 2022
Cited by 7 | Viewed by 1686
Abstract
Excessive glucose metabolism and disruptions in Wnt signaling are important molecular changes present in oral cancer cells. The aim of this study was to evaluate the effects of the combinatorial use of glycolysis and Wnt signaling inhibitors on viability, cytotoxicity, apoptosis induction, cell [...] Read more.
Excessive glucose metabolism and disruptions in Wnt signaling are important molecular changes present in oral cancer cells. The aim of this study was to evaluate the effects of the combinatorial use of glycolysis and Wnt signaling inhibitors on viability, cytotoxicity, apoptosis induction, cell cycle distribution and the glycolytic activity of tongue carcinoma cells. CAL 27, SCC-25 and BICR 22 tongue cancer cell lines were used. Cells were treated with inhibitors of glycolysis (2-deoxyglucose and lonidamine) and of Wnt signaling (PRI-724 and IWP-O1). The effects of the compounds on cell viability and cytotoxicity were evaluated with MTS and CellTox Green tests, respectively. Apoptosis was evaluated by MitoPotential Dye staining and cell cycle distribution by staining with propidium iodide, followed by flow cytometric cell analysis. Glucose and lactate concentrations in a culture medium were evaluated luminometrically. Combinations of 2-deoxyglucose and lonidamine with Wnt pathway inhibitors were similarly effective in the impairment of oral cancer cells’ survival. However, the inhibition of the canonical Wnt pathway by PRI-724 was more beneficial, based on the glycolytic activity of the cells. The results point to the therapeutic potential of the combination of low concentrations of glycolytic modulators with Wnt pathway inhibitors in oral cancer cells. Full article
(This article belongs to the Special Issue Cancer Cell Metabolism 2.0)
Show Figures

Figure 1

Back to TopTop